Stocktoria
Protalix BioTherapeutics, Inc. PLX
NYSE American · XASE · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2010-09-06
Protalix BioTherapeutics, Inc. statistics & valuation
Market cap as of 2026-06-30. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | 19.0% | 8.7% |
| Operating margin | -10.4% | 7.3% | 16.0% | -27.3% | -53.4% | 4.3% | -19.6% | -56.4% | -163.8% | -360.5% |
| Net margin | -12.5% | 5.5% | 12.7% | -31.3% | -71.9% | -10.4% | -33.4% | -77.3% | -395.9% | -319.2% |
| FCF margin | -25.8% | 13.8% | -3.8% | -53.8% | -30.6% | -42.5% | -36.5% | -24.6% | -52.0% | -358.2% |
| Return on assets | -8.0% | 4.0% | 9.8% | -26.8% | -37.4% | -9.6% | -40.3% | -43.3% | -115.5% | -35.7% |
| Return on equity | -13.7% | 6.8% | 24.8% | 140.3% | 457.0% | 24.1% | 26.0% | 50.0% | 283.3% | 294.9% |
| Current ratio | 2.51 | 2.34 | 1.54 | 1.38 | 1.86 | 0.64 | 0.81 | 2.09 | 2.75 | 1.09 |
Source: SEC EDGAR filings · CIK 0001006281 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.